trial

A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder

NCTId NCT02006628
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 88 (actual)
Sponsored by Jazz Pharmaceuticals
Primary completion 2015-01-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
88 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-02-25
Primary completion
2015-01-08
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
GWP42003

Sponsors

Jazz PharmaceuticalsLead Sponsor

Sites

0 total

Linked catalysts

1
A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizop — primary completion2015-01-08

Facts & assertions

4 sourced
Enrollment
88
Phase
PHASE2
Primary Completion Date
2015-01-08
Status
COMPLETED
relationships
The graph out of here
drug
GWP42003
drug
lead_sponsor
Jazz Pharmaceuticals
company
indication
Schizophrenia
indication
Schizophrenia
indication
Schizophrenia-related Psychotic Disorder
indication